主角退出武田利润分享协议,将获4亿美元现金。
Protagonist to opt out of Takeda profit-sharing deal, will receive $400M in cash
生物技术与制药领域的最新动态
Protagonist to opt out of Takeda profit-sharing deal, will receive $400M in cash
Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer
Salma Health raises $80M for its clinics to treat brain health
OrbiMed jumps to number one on the top 100 list of biotech venture investors
Lilly's GLP-1 pill beats Novo’s in diabetes trial, has more side effects
Japan's Asahi Kasei to buy German biotech Aicuris for $920M
Sarepta CEO Doug Ingram to step down
Gilead, Merck plan to debut new daily HIV pills
Make way, Camzyos: Cytokinetics touts promising early launch for rival heart drug
Charles River sells its CDMO and European discovery businesses
Accent axes a cancer study; Werewolf considers its options
Alkermes CEO Richard Pops to retire after 35-year tenure
States sue Kennedy over US childhood vaccine overhaul
Novo Nordisk teams with Langer-founded biotech for oral obesity drugs
Polymer nanoparticle startup BreezeBio raises $60M for mRNA diabetes therapy
GSK to buy pulmonary hypertension biotech 35Pharma for $950M
HHS commits up to $144M to study anti-aging approaches via ARPA-H
Novo Nordisk to slash Wegovy list price in half in 2027
Industry groups lay legal groundwork against pricing demos
UCLA spinout raises $11M to test microbiome-based weight loss therapy